Clinical Trials · NCT02217839

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

Name: Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Octreotide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Aspireo Pharmaceuticals Limited
Enrollment: 42
Start date: Apr 2012
Locations: See registry
Primary endpoint: Number of serious adverse events or withdrawals due to adverse events. Laboratory investigations (including biochemistry, hematology, and urinalysis), vital signs (blood pressure, pulse rate), and 12-lead ECG.

View Octreotide compound reference